Transplantation of encapsulated human Leydig-like cells: A novel option for the treatment of testosterone deficiency
Transplantation of encapsulated human Leydig-like cells: A novel option for the treatment of testosterone deficiency
复制标题
封装的人间质样细胞移植：治疗睾酮缺乏的新选择
DOI：
10.1016/j.mce.2020.111039
复制
发表时间：
2021-01-01
影响因子：
4.1
通讯作者：
Deng, Chunhua
中科院分区：
文献类型：
--
作者：
Feng, Xin;Xia, Kai;Deng, Chunhua
Previous studies have demonstrated that the transplantation of alginate-poly-L-lysine-alginate (APA)-encapsulated rat Leydig cells (LCs) provides a promising approach for treating testosterone deficiency (TD). Nevertheless, LCs have a limited capacity to proliferate, limiting the efficacy of LC transplantation therapy. Here, we established an efficient differentiation system to obtain functional Leydig-like cells (LLCs) from human stem Leydig cells (hSLCs). Then we injected APA-encapsulated LLCs into the abdominal cavities of castrated mice without an immunosuppressor. The APA-encapsulated cells survived and partially restored testosterone production for 90 days in vivo. More importantly, the transplantation of encapsulated LLCs ameliorated the symptoms of TD, such as fat accumulation, muscle atrophy and adipocyte accumulation in bone marrow. Overall, these results suggest that the transplantation of encapsulated LLCs is a promising new method for testosterone supplementation with potential clinical applications in TD.
